North America Biochips Market (2025-2030)
The North America Biochips Market was valued at $6445.7 Million in 2025 and projected to reach to $9656.4 Million by 2030, representing a compound annual growth rate of 8.4%. North America's biochips market is poised for sustained expansion, driven by increasing adoption of point-of-care diagnostics, growing prevalence of chronic diseases, and significant investments in healthcare digitalization.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Biochips Market Trends and Insights
- This 8.4% compound annual growth rate reflects North America's leadership in healthcare innovation, advanced diagnostics, and personalized medicine adoption.
- North America benefits from strong regulatory frameworks, substantial R&D investments, and a concentration of leading biochip manufacturers and research institutions. The North America biochips market is driven by increasing demand for point-of-care diagnostics, drug discovery acceleration, and genomic analysis applications.
- North America's healthcare infrastructure and reimbursement policies support rapid commercialization of biochip technologies.
- Between 2025 and 2030, North America is expected to maintain its position as a key growth engine, supported by rising prevalence of chronic diseases and growing adoption of lab-on-chip solutions across clinical and research settings. North America's competitive advantage stems from technological innovation, strategic partnerships, and significant venture capital funding in the biochip sector.
- North America continues to attract global investment and talent, positioning the region for sustained market expansion through 2030..
Key Market Statistics
- CAGR (2025-2030) 8.4% CAGR
- Market Size, 2025 ~USD 6445.7 Million
- Forecast, 2030 ~USD 9656.4 Million
- Geography North America
North America Biochips Market Overview
Market Leadership Position :
North America commands 66.8% of the global biochips market, with the US alone representing $8,691.9 million in 2025, establishing the region as the dominant force in biochip innovation and commercialization.
Strong R&D Investment Ecosystem :
The region benefits from substantial government and private sector R&D funding, world-class research institutions, and biotech clusters in California, Massachusetts, and the Northeast corridor driving continuous innovation in diagnostic and therapeutic biochips.
Personalized Medicine Adoption :
North American healthcare systems are rapidly integrating biochips for personalized diagnostics and treatment planning, supported by advanced healthcare infrastructure and increasing patient demand for precision medicine solutions.
Regulatory Framework Advantage :
Established FDA approval pathways and clear regulatory guidelines in the US and Canada provide manufacturers with streamlined market entry, accelerating product launches and commercialization timelines compared to other regions.
North America Biochips Market Dynamics
- The region's 8.4% CAGR reflects strong demand from hospitals, diagnostic laboratories, and research institutions seeking advanced diagnostic solutions.
- Personalized medicine initiatives and genomic sequencing applications are particularly fueling market growth across the US and Canada. Looking ahead to 2030, North America will continue to lead global biochip innovation through strategic partnerships between biotech firms, pharmaceutical companies, and healthcare providers.
- Emerging applications in organ-on-chip technology, drug testing, and disease monitoring will create new revenue streams.
- The region's mature healthcare infrastructure, coupled with favorable reimbursement policies and increasing insurance coverage for biochip-based diagnostics, will sustain the projected growth trajectory to $9,656.4 million by 2030..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- North America's biochips market will grow from $6,445.7M (2025) to $9,656.4M (2030) at an 8.4% CAGR.
- North America leads in biochip innovation due to advanced healthcare infrastructure and substantial R&D investment.
- Point-of-care diagnostics and personalized medicine are primary growth drivers in North America.
- North America's regulatory environment and reimbursement policies accelerate biochip commercialization and adoption.
Biochips Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MICROFLUIDICS (Fabrication Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.8% from 2025 to 2030 |
| Largest Segment | MICROARRAYS (Fabrication Technology) |
| Market Size Base Year (Billions) | ~USD 14.01 (2025) |
| Revenue Forecast (Billions) | ~USD 21.36 (2030) |
| Segments Covered | Products & Services, Type, Application, Fabrication Technology, End User, Product & Service |
North America Biochips Market Report Segmentation
6 segment dimensions are covered across the global market.
By Products & Services
- Consumables
- Instruments
- Software & Services
By Type
- Cell Arrays
- Dna Chips
- Lab-On-A-Chip
- Protein Chips
- Tissue Arrays
By Application
- Agricultural Biotechnology
- Cancer Diagnosis & Treatment
- Clinical Diagnostic
- Diagnostics
- Drug Discovery
- Expression Profiling
- Gene Expression
- Genomics
- High-Throughput Screening
- Ivd & Poc
- Other Dna Chip Applications
- Other Loac Applications
- Other Protein Chip Applications
- Proteomics
- Snp Genotyping
By Fabrication Technology
- Microarrays
- Microfluidics
By End User
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations
- Hospitals & Diagnostic Centers
- Other End Users
By Product & Service
- Consumables
- Instruments
- Software & Services
Target Audience
- Biochip Manufacturers & Developers : Manufacturers need North America market data to identify growth opportunities, benchmark competitive positioning, and develop region-specific product strategies for the world's largest biochips market.
- Healthcare Providers & Hospitals : Hospital networks and diagnostic centers require market insights to evaluate biochip technology adoption, assess vendor landscapes, and make informed procurement decisions aligned with clinical and financial objectives.
- Pharmaceutical & Biotech Companies : Pharma firms need North America biochips market intelligence to identify partnership opportunities, evaluate acquisition targets, and understand diagnostic integration trends for drug development and companion diagnostics.
- Investment & Private Equity Firms : Investors require detailed North America market analysis to identify high-growth biochip companies, assess market valuations, evaluate exit opportunities, and make informed capital allocation decisions.
- Healthcare Policy & Government Agencies : Policymakers and health agencies need market data to understand biochips adoption trends, assess healthcare innovation progress, and develop evidence-based regulations and reimbursement policies.
Key Companies in the North America Biochips Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Custom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions, |
| DECODE GENETICS | Iceland | Private Company | Internal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects, |
| JABIL | United States | Public Company | Regulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem), |
| AT&S | Canada | Public Company | Turnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration, |
| X-FAB | Belgium | Public Company | Automotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes), |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other, |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents), |
| CEPHEID | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics), |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| REVVITY | United States | Public Company | Diagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions, |
ATS AUTOMATION TOOLING SYSTEMS INC
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.
DECODE GENETICS
Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.
JABIL
Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.
AT&S
AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.
X-FAB
X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.
GE HEALTHCARE
GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
ILLUMINA, INC.
Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.
QIAGEN
Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
ABBOTT
Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.
STANDARD BIOTOOLS
Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.
10X GENOMICS
10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.
CEPHEID
Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.
REVVITY
Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 8691.9 Million |
| Canada | USD 964.6 Million |
Country market size visualization
Reasons to Buy this Report
- Market Size & Growth Validation : Access precise market valuations for North America ($6,445.7M in 2025) and country-level breakdowns for the US and Canada, enabling accurate financial forecasting and investment decision-making.
- Competitive Landscape Intelligence : Understand the competitive dynamics specific to North America's biochips ecosystem, including key players, market consolidation trends, and strategic positioning within the region's dominant market.
- Regulatory & Reimbursement Insights : Gain detailed knowledge of FDA approval pathways, insurance coverage policies, and healthcare reimbursement mechanisms unique to North America that directly impact market adoption and profitability.
- Regional Growth Drivers : Identify North America-specific growth catalysts including personalized medicine adoption, chronic disease prevalence, healthcare IT investments, and R&D funding trends shaping market expansion.
- Strategic Market Entry Planning : Develop targeted go-to-market strategies for North America with country-specific insights on market maturity, customer preferences, distribution channels, and partnership opportunities in the US and Canada.
Frequently asked questions
What is the projected market size for biochips in North America by 2030?
North America's biochips market is projected to reach $9,656.4 million by 2030, growing from $6,445.7 million in 2025.
What is the CAGR for North America's biochips market?
North America's biochips market is expected to grow at a compound annual growth rate of 8.4% between 2025 and 2030.
What are the main drivers of biochip market growth in North America?
Key drivers in North America include increasing demand for point-of-care diagnostics, personalized medicine adoption, drug discovery acceleration, and growing prevalence of chronic diseases.
Why is North America a leading region for biochips?
North America leads due to advanced healthcare infrastructure, strong regulatory frameworks, substantial R&D investments, and a high concentration of innovative biochip manufacturers and research institutions.
How does North America's biochip market compare to global growth?
North America's 8.4% CAGR is slightly below the global average of 8.8%, reflecting mature market dynamics while maintaining strong absolute growth in the region.
RESEARCH METHODOLOGY
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.
Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Academic Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Biochip Manufacturers and Distributors
- DNA & Gene Chip Manufacturers and Distributors
- Protein Microarray Manufacturers and Distributors
- Lab-on-a-Chip Manufacturers and Distributors
- Cell & Tissue Array Manufacturers and Distributors
Report Objectives
- To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Get the Full Biochips Market Report
Full forecast, segment splits, and company analysis for all Biochips Market.
- Canada Biochips Market
- US Biochips Market
- Germany Biochips Market
- UK Biochips Market
- France Biochips Market
- Italy Biochips Market
- Spain Biochips Market
- Netherlands Biochips Market
- China Biochips Market
- Japan Biochips Market
- India Biochips Market
- Australia Biochips Market
- South Korea Biochips Market
- Thailand Biochips Market
- New Zealand Biochips Market
- Brazil Biochips Market
- Mexico Biochips Market
- Rest Of Europe Biochips Market
- Rest Of Asia Pacific Biochips Market
- Rest Of Latin America Biochips Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
